GlassScriptPhysician profile
Charles D Cohn
NPI 1538168232
$5,292.80
in general payments reported to CMS, 2019-2025
29 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,312 · 2020: $1,089 · 2021: $1,220 · 2022: $633 · 2023: $295 · 2024: $204 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,200.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $722.49 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $619.99 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $366.93 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $344.77 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $276.35 | 2019-2023 | Synthroid |
| Kowa Pharmaceuticals America, INC. | $239.97 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $206.87 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $194.33 | 2019-2021 | |
| Amarin Pharma, INC. | $174.12 | 2019-2020 | |
| Pfizer INC. | $146.92 | 2019-2022 | |
| Atricure, INC. | $142.33 | 2025 | Synergy Ablation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.72 | 2019-2022 | |
| Astellas Pharma US INC | $109.20 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $55.94 | 2023-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $44.59 | 2019-2025 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $40.53 | 2022 | |
| Sanofi Pasteur INC. | $34.92 | 2020-2022 | |
| Esperion Therapeutics, INC. | $30.97 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $30.80 | 2021 | |
| Ironwood Pharmaceuticals, INC | $30.42 | 2019 | |
| Radius Health, INC. | $30.01 | 2019 | |
| Eisai INC. | $22.50 | 2021 | |
| Abbott Laboratories | $22.40 | 2021 | |
| Sumitomo Pharma America, INC. | $22.14 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $16.73 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.67 | 2025 | Voquezna |
| Shire North American Group INC | $12.29 | 2019 | |
| Next Science LLC | $11.74 | 2023 | Xperience, Blastx, Surgx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Cohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.